Second, since cancer cells secrete cytokines to evade drug-induced death (115), and oxaliplatin, a component of FOLFOX, induces a WNT/β-catenin target IL-6 (116, 117), we determined whether our resistant cells and sensitive cells differentially secret WNT3A ligands in response to FOLFOX treatment. This evidence concerns the gene WNT3A and cancer.